Sadjadieh G, et al. - In an unselected ST-segment elevation myocardial infarction (STEMI)-population, researchers examined the incidence of bleeding and mortality over 1 year. They also compared participants with non-participants of a randomized all-comer clinical trial (The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction [DANAMI-3]). They assessed 2,490 consecutive STEMI-patients undergoing primary percutaneous coronary intervention in a single, large, tertiary heart-center, via hospital-charts and bleedings classified according to TIMI and BARC criteria. Significantly more TIMI minor/major bleedings (TMMBs) occurred within 30 days among clinical trial (DANAMI-3) non-participants vs participants. A high rate of TMMBs was attributed to patients with resuscitated cardiac arrest, anemia, and killip-class > 2. Bleeding incidences from clinical trials cannot be translated to an unselected STEMI population.